Market research
0OT.F Ocular Therapeutix, Inc
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 23.43
- Dividend yield
- Not available
- Beta
- 0.99
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 1B
- P/E ratio
- Not available
- Analyst target
- 23.43
- Dividend yield
- Not available
- Beta
- 0.99
About
About Ocular Therapeutix, Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Research context
Ocular Therapeutix, Inc appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the 0OT.F discussion.
5 years, 6 months ago
Ocular Therapeutix, Inc is currently in a long term downtrend where the price is trading 18.7% below its 200 day moving average.
From a valuation standpoint, the stock is 95.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 59.4.
Ocular Therapeutix, Inc's total revenue rose by 225.8% to $7M since the same quarter in the previous year.
Its net income has dropped by 229.1% to $-86M since the same quarter in the previous year.
Finally, its free cash flow grew by 67.6% to $-6M since the same quarter in the previous year.
Based on the above factors, Ocular Therapeutix, Inc gets an overall score of 3/5.